← Back to Search

Patients with RA-ILD for Rheumatoid Arthritis (MOUNTAIN Trial)

N/A
Recruiting
Led By Joyce S Lee
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5-years
Awards & highlights

MOUNTAIN Trial Summary

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.

Eligible Conditions
  • Rheumatoid Arthritis
  • Interstitial Lung Disease

MOUNTAIN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5-years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5-years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluating the role of novel quantitative imaging
Secondary outcome measures
Comparing peripheral blood telomere length (PB-TL)
Defining peripheral blood transcriptomic profiles
Exploring if a composite profile more accurately identifies progressive RA-ILD

MOUNTAIN Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with RA-ILDExperimental Treatment3 Interventions
Assessments include: Clinical: height, weight, oxygen saturation at rest, and 6-minute walk test. Rheumatological: study Rheumatologist will document rheumatoid arthritis symptoms and clinical findings at baseline and follow-up. Pulmonary Function Testing: data will be collected from clinically performed spirometry and diffusing capacity for carbon monoxide. High-resolution computed tomography (HRCT) imaging: HRCT scans will be collected at baseline and 12 months in line with standard of care for treatment of RA-ILD. Lab specimens: peripheral blood will be obtained for DNA, RNA, serum, and plasma at baseline and at 12 months for all sites or every 3-4 months in Colorado. Buccal swabs (cheek) will also be collected once each year. Information collected: will include demographics, co-morbidities, disease history, medication history, pulmonary function, radiographic imaging, and transplant/survival status through questionnaires and medical chart review.

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,742 Previous Clinical Trials
2,152,309 Total Patients Enrolled
6 Trials studying Rheumatoid Arthritis
2,282 Patients Enrolled for Rheumatoid Arthritis
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,843 Previous Clinical Trials
47,816,658 Total Patients Enrolled
5 Trials studying Rheumatoid Arthritis
585 Patients Enrolled for Rheumatoid Arthritis
University of MichiganOTHER
1,800 Previous Clinical Trials
6,378,690 Total Patients Enrolled
3 Trials studying Rheumatoid Arthritis
170 Patients Enrolled for Rheumatoid Arthritis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
2024. "Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06397677.
All > Kansas City > Colorado Springs
~300 spots leftby Jan 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top